Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
- Citation:
- Oncologist vol 22 (2) 189-198
- Year:
- 2017
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-internal-user
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Book Volume:
- 6
- Parents:
- 2040
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA 033601, NIA 5R21AG042894; CA180821, U10CA180882, VA Career Development Award; CA47559 and NIA 5R21AG042894; CA 47577; CA xxxx; CA xxxx; CA 41287; NIA 5R21AG042894 and PCFB, , U10 CA033601, R21 AG042894, U10 CA180821, U10 CA180836, U10 CA180857, U10 CA180882, P01 CA142538, U10 CA180838, U10 CA180866
- Corr. Author:
- Authors:
- Xiaofei Wang Xiaoyi Wang Lydia Hodgson Stephen L. George Daniel J. Sargent Nate R. Foster Apar Kishor Ganti Thomas E. Stinchcombe Jeffrey Crawford Robert Kratzke Alex A. Adjei Hedy L. Kindler Everett E. Vokes Herbert Pang
- Networks:
- LAPS-IL057, LAPS-MN026, LAPS-NC010, MN022, NE003
- Study
- Alliance-A151724
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-8435, CALGB-8638, CALGB-8833, CALGB-8933, CALGB-9031, CALGB-30101, CALGB-30107, CALGB-30307, CALGB-30601, CALGB-39807, CALGB-9131, CALGB-9234, CALGB-9530, CALGB-9631, CALGB-9733, NCCTG-N0021, NCCTG-N0623
- Phases:
- N/A, 2
- Keywords:
- Malignant mesothelioma, Surrogate endpoint, Progression‐free survival, Overall survival, Risk factors